Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
China
Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China, Beijing, Beijing Municipality The first affiliated hospital of fujian medical university, Fuzhou, Fujian Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong The Third Bethune Hospital of Jilin University, Changchun, Jilin Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai Municipality